Senseonics Gets Green Light from FDA on Implantable Glucose Monitoring System
| Printer friendly version
Senseonics recently received Premarket Approval from the Food and Drug Administration (FDA) for its Eversense® Continuous Glucose Monitoring (CGM) System. According to Senseonics, the Eversense® CGM System is the first and only implantable device to allow for continuous blood-glucose monitoring for as long as three months.
The Eversense ® CGM system includes an implantable glucose sensor, a wearable transmitter, and the Eversense Mobile App. Senseonics advertises the sensor as utilizing fluorescent, glucose indicating polymer technology to measure glucose in the interstitial fluid. According to Senseonics, measurements from the sensor are conveyed to the wearable transmitter, which wirelessly communicates with the Eversense Mobile App to display real-time glucose measurements, trends, and alerts.
Commenting on the FDA approval, Senseonics President and CEO Tim Goodnow stated:
“With the parallel trends of wearable personal devices and medical implantables for people to manage their health, this product exemplifies the natural evolution for diabetes devices, and Senseonics is excited to help lead the way.”
Related
Aaron Johnson
Aaron S. Johnson is an associate in the firm's Orange County office. His practice includes patent prosecution, IP litigation, and due diligence.
Aaron received his Bachelor of Science in Civil Engineering from the University of California, Irvine. Aaron later received his Master of Science degree in Civil Engineering from the University of California, Berkeley, specifically within the Structural Engineering, Mechanics, and Materials Department (SEMM). Aaron's master's thesis involved research and analysis of seismic base isolation systems. While at UC Berkeley, Aaron worked as a graduate student instructor for first-year students majoring in mechanical and civil engineering. After graduating, Aaron worked as a structural engineer and earned his professional engineer license.
Aaron earned his law degree from the University of California, Irvine, where he served as a teaching assistant for a first-year Lawyering Skills course and as a research Editor on the UC Irvine Law Review. Aaron also worked at the UCI Intellectual Property, Arts, and Technology Clinic.
Mr. Johnson worked as a summer associate in 2016 before joining the firm as an associate in 2017.
View all posts published by Aaron Johnson »
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
Share